Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2020-07-01
Saila:	Endocrinology, Diabetes & Metabolism
Gaiak:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Sarrera elektronikoa:	https://doi.org/10.1002/edm2.159
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!